Development of non-integrating lentiviral vectors for safer gene therapy
开发非整合慢病毒载体以实现更安全的基因治疗
基本信息
- 批准号:BB/E000045/1
- 负责人:
- 金额:$ 41.7万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2007
- 资助国家:英国
- 起止时间:2007 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
During the last few years gene therapy has been used to treat children with adenosine deaminase (ADA) deficiency and common ?-chain, or X-linked, severe combined immunodeficiency (SCID). Retroviral vectors were used to deliver the therapeutic gene, which was able to integrate into the genome of host cells and cure the disease. Unfortunately, three children in a French trial for X-linked SCID have developed T cell leukaemia following the integration of retroviral DNA into the human genome. The leukemia in these patients was caused by the therapeutic gene integrating into a dangerous location in a host cell chromosome. Integration of the gene into this location caused an event called insertional mutagenesis and resulted in cell transformation and cancer. The outcome of this clinical trial emphasizes the need to develop safer gene therapy vectors. This can be achieved by preventing the integration of a therapeutic gene into an unwanted and dangerous area of the patients' genome. Instead of retroviruses, our group studies lentiviruses as gene therapy vectors. Lentiviruses can package large amounts of DNA, and unlike retroviruses they can infect non-dividing as well as dividing cells. These two properties mean that properly engineered lentiviruses will have vast potential to treat genetic diseases of many tissue and organ types. Like retroviruses, lentiviruses integrate into the patients own genome. This is beneficial because it means that long-term correction of a genetic defect can theoretically be achieved with just one administration of the lentivirus. However, as discussed above, there is a risk of disrupting normal DNA in the patient's genome. Therefore, we have proposed to engineer lentiviruses that eliminate this risk of insertional mutagenesis while retaining all the helpful properties that make lentiviruses such a promising vehicle for gene therapy. Insertional mutagenesis can be prevented by inhibiting integration of the lentivirus DNA into the patient's genome. Lentiviruses integrate by using an integrase protein. We are in the process of generating lentiviruses with an altered, ineffective integrase protein. These newly engineered lentiviruses will be tested for their ability to safely deliver genes into various non-dividing cell types. Since the cells do not divide, we expect the newly delivered gene to stay in the cell but not to integrate into the cell's genome. This therapeutic gene will be maintained as a separate piece of DNA that will not interfere with normal cellular DNA functions. We expect these non-integrating lentivirus vectors to be most useful in cells such as retina and muscle. Furthermore, since the therapeutic gene will be maintained indefinitely inside the cell, only one dose of the lentivirus is necessary. Such a system will translate into a safer and simpler approach than the currently available gene therapy techniques.
在过去的几年中,基因疗法已被用于治疗儿童腺苷脱氨酶(ADA)缺乏症和常见?-链,或x连锁,严重联合免疫缺陷(SCID)。逆转录病毒载体被用来传递治疗基因,该基因能够整合到宿主细胞的基因组中并治愈疾病。不幸的是,在法国的一项x连锁SCID试验中,三名儿童在将逆转录病毒DNA整合到人类基因组后患上了T细胞白血病。这些患者的白血病是由治疗基因整合到宿主细胞染色体的危险位置引起的。基因整合到这个位置引起了一个叫做插入突变的事件,导致细胞转化和癌症。这项临床试验的结果强调了开发更安全的基因治疗载体的必要性。这可以通过防止治疗基因整合到患者基因组中不想要的和危险的区域来实现。我们小组研究的不是逆转录病毒,而是慢病毒作为基因治疗载体。慢病毒可以包装大量的DNA,与逆转录病毒不同,它们既可以感染非分裂细胞,也可以感染分裂细胞。这两个特性意味着经过适当改造的慢病毒在治疗许多组织和器官类型的遗传疾病方面具有巨大的潜力。像逆转录病毒一样,慢病毒会整合到患者自身的基因组中。这是有益的,因为这意味着理论上只需一次使用慢病毒就可以实现对遗传缺陷的长期纠正。然而,如上所述,存在破坏患者基因组中正常DNA的风险。因此,我们建议设计慢病毒,以消除这种插入突变的风险,同时保留所有使慢病毒成为基因治疗有前途的载体的有益特性。插入突变可以通过抑制慢病毒DNA整合到患者基因组中来预防。慢病毒通过整合酶蛋白进行整合。我们正在用一种改变了的、无效的整合酶蛋白制造慢病毒。这些新设计的慢病毒将被测试其安全将基因传递到各种非分裂细胞类型的能力。由于细胞不分裂,我们预计新传递的基因将留在细胞中,但不会整合到细胞的基因组中。这种治疗性基因将作为一个独立的DNA片段保存,不会干扰正常的细胞DNA功能。我们预计这些非整合慢病毒载体在视网膜和肌肉等细胞中最有用。此外,由于治疗基因将在细胞内无限期地维持,因此只需要一次剂量的慢病毒。这样的系统将转化为一种比目前可用的基因治疗技术更安全、更简单的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adrian Thrasher其他文献
929. Functional Potential of Human T Cells Following Lentiviral Suicide Gene Transduction
- DOI:
10.1016/j.ymthe.2006.08.1020 - 发表时间:
2006-01-01 - 期刊:
- 影响因子:
- 作者:
Taylor Mackey;Joanne Buddle;Christine Kinnon;Adrian Thrasher;Hubert Gaspar;Waseem Qasim - 通讯作者:
Waseem Qasim
<strong>WASP-deficient hematopoietic progenitor cells mobilize in response to G-CSF and can restore hematopoiesis in mice</strong>
- DOI:
10.1016/j.bcmd.2007.10.029 - 发表时间:
2008-03-01 - 期刊:
- 影响因子:
- 作者:
Sabine Charrier;Mike Blundell;Marie Liabeuf;Fawzia Louache;William Vainchenker;Adrian Thrasher;Anne Galy - 通讯作者:
Anne Galy
<strong>Case report of the first patient treated with ex-vivo autologous haematopoietic stem cell gene therapy transplant in mucopolysaccharidosis type IIIA</strong>
- DOI:
10.1016/j.ymgme.2019.11.225 - 发表时间:
2020-02-01 - 期刊:
- 影响因子:
- 作者:
Jane Louise Kinsella;Heather Church;Wendy Ogden;Ceri Jones;Karen Buckland;Christine Rivat;Adrian Thrasher;Katie Snell;Diego Leon-Rico;Fred Vaz;Frits Wijburg;Simon Jones;Brian Bigger;Robert Wynn - 通讯作者:
Robert Wynn
Cellular Rheology and Hydraulics
- DOI:
10.1016/j.bpj.2011.11.3064 - 发表时间:
2012-01-31 - 期刊:
- 影响因子:
- 作者:
Emadaldin Moeendarbary;Leo Valon;Andrew Harris;Dale Moulding;Adrian Thrasher;Eleanor Stride;L. Mahadevan;Guillaume Charras - 通讯作者:
Guillaume Charras
458. Development of Non-Integrating and Site- Specifically Integrating Lentiviral Vectors
- DOI:
10.1016/j.ymthe.2006.08.527 - 发表时间:
2006-01-01 - 期刊:
- 影响因子:
- 作者:
Luis Apolonia;Simon Waddington;Mary Collins;Adrian Thrasher;Nicola Philpott - 通讯作者:
Nicola Philpott
Adrian Thrasher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adrian Thrasher', 18)}}的其他基金
UCOE-based lentiviral vectors for effective and safe gene therapy
基于 UCOE 的慢病毒载体用于有效且安全的基因治疗
- 批准号:
BB/F015526/1 - 财政年份:2008
- 资助金额:
$ 41.7万 - 项目类别:
Research Grant
Clinical trial of self-inactivating vectors for gene therapy of X-linked Severe Combined Immunodeficiency (SCID-X1)
自失活载体用于X连锁严重联合免疫缺陷症(SCID-X1)基因治疗的临床试验
- 批准号:
G0501969/1 - 财政年份:2006
- 资助金额:
$ 41.7万 - 项目类别:
Research Grant
相似国自然基金
基于深穿透拉曼光谱的安全光照剂量的深层病灶无创检测与深度预测
- 批准号:82372016
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
Non-CG DNA甲基化平衡大豆产量和SMV抗性的分子机制
- 批准号:32301796
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
long non-coding RNA(lncRNA)-activatedby TGF-β(lncRNA-ATB)通过成纤维细胞影响糖尿病创面愈合的机制研究
- 批准号:LQ23H150003
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
- 批准号:82370865
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
染色体不稳定性调控肺癌non-shedding状态及其生物学意义探索研究
- 批准号:82303936
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
犬尿氨酸酶KYNU参与非酒精性脂肪肝进展为肝纤维化的作用和机制研究
- 批准号:82370874
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
变分法在双临界Hénon方程和障碍系统中的应用
- 批准号:12301258
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
BTK抑制剂下调IL-17分泌增强CD20mb对Non-GCB型弥漫大B细胞淋巴瘤敏感性
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
Non-TAL效应子NUDX4通过Nudix水解酶活性调控水稻白叶枯病菌致病性的分子机制
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
一种新non-Gal抗原CYP3A29的鉴定及其在猪-猕猴异种肾移植体液排斥反应中的作用
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
相似海外基金
Integrating Tailored Postoperative Opioid Tapering and Pain Management Support for Patients on Long-Term Opioid Use Presenting for Spine Surgery (MIRHIQL)
为脊柱手术中长期使用阿片类药物的患者整合定制的术后阿片类药物逐渐减量和疼痛管理支持 (MIRHIQL)
- 批准号:
10722943 - 财政年份:2023
- 资助金额:
$ 41.7万 - 项目类别:
Multi-ethnic risk prediction for complex human diseases integrating multi-source genetic and non-genetic information
整合多源遗传与非遗传信息的人类复杂疾病多民族风险预测
- 批准号:
10754773 - 财政年份:2023
- 资助金额:
$ 41.7万 - 项目类别:
Long-lasting recovery of lysosomal acid lipase deficiency using non-viral delivery of non-integrating episomal DNA constructs.
使用非整合附加型 DNA 构建体的非病毒递送来长期恢复溶酶体酸性脂肪酶缺乏症。
- 批准号:
478865 - 财政年份:2023
- 资助金额:
$ 41.7万 - 项目类别:
Operating Grants
Integrating eye-tracking and ECG methodologies for remote infant neurocognitive assessments in the home
整合眼动追踪和心电图方法,在家中进行远程婴儿神经认知评估
- 批准号:
10773680 - 财政年份:2023
- 资助金额:
$ 41.7万 - 项目类别:
An acquisition and analysis pipeline for integrating MRI and neuropathology in TBI-related dementia and VCID
用于将 MRI 和神经病理学整合到 TBI 相关痴呆和 VCID 中的采集和分析流程
- 批准号:
10810913 - 财政年份:2023
- 资助金额:
$ 41.7万 - 项目类别:
NIDA Clinical Trials Network: New York Node - GY22 Integrating MOUD in Non-Medical Settings to Improve Treatment and Retention of Black/AA Persons
NIDA 临床试验网络:纽约节点 - GY22 在非医疗环境中整合 MOUD,以改善黑人/AA 人的治疗和保留
- 批准号:
10809985 - 财政年份:2023
- 资助金额:
$ 41.7万 - 项目类别:
Integrating Computational and Experimental Models to Predict Toxicity of the Pancreas
整合计算和实验模型来预测胰腺的毒性
- 批准号:
10576042 - 财政年份:2023
- 资助金额:
$ 41.7万 - 项目类别:
IGE: Integrating Data Science into the Applied Mathematics PhD: Generalized Skills for Non-Academic Careers
IGE:将数据科学融入应用数学博士:非学术职业的通用技能
- 批准号:
2325446 - 财政年份:2023
- 资助金额:
$ 41.7万 - 项目类别:
Standard Grant
Integrating liquid biopsy-based epigenetic and imaging modalities to evaluate disease response in multiple myeloma
整合基于液体活检的表观遗传学和成像方式来评估多发性骨髓瘤的疾病反应
- 批准号:
10651370 - 财政年份:2023
- 资助金额:
$ 41.7万 - 项目类别:
Clinical Trials Network: Admin Supplement: Integrating MOUD with BUP in Non-medical Community Settings
临床试验网络:管理补充:在非医疗社区环境中将 MOUD 与 BUP 集成
- 批准号:
10801347 - 财政年份:2023
- 资助金额:
$ 41.7万 - 项目类别: